ArticleJournal of translational medicine2026
RHOJ derived peptide promotes chemosensitivity by inhibiting glutamine metabolism in gastric cancer.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemoresistance is a cause of chemotherapy failure in gastric cancer (GC) treatment. Recent studies have shown that the dysregulation of glutamine metabolism plays a pivotal role in promoting chemoresistance. While small-molecule inhibitors targeting glutamine metabolism have been investigated, peptide-based compounds have attracted increasing attention because of their high specificity and low toxicity. Endogenous or rationally designed peptides have shown potential for inducing apoptosis, disrupting cancer-related signaling pathways, and overcoming drug resistance in various cancers. However, the potential of functional peptides to target glutamine metabolism and reverse drug resistance in the context of GC has not been thoroughly explored.
methodsWe performed proteomic profiling to identify upregulated proteins in cisplatin-sensitive GC cells, from which peptides were derived for functional screening. A RHOJ-derived peptide (peptide 1) was identified and validated as a candidate chemosensitizer. Untargeted metabolomics, flow cytometry, molecular docking, molecular dynamics simulations, fluorescence imaging, and a subcutaneous xenograft model were used to investigate the mechanism through which peptide 1 modulates GLUL-mediated glutamine metabolism and reverses cisplatin resistance.
resultsIn this study, we found that glutamine metabolism was enhanced in cisplatin-resistant GC cells and that a peptide which derived from RHOJ (peptide 1) increased the sensitivity of resistant cells to chemotherapy. Molecular docking revealed that this peptide could bind to glutamine synthetase (GLUL), a key enzyme in the glutamine metabolism pathway. Mechanistically, peptide 1 inhibited glutamine production, increased ROS levels, induced DNA damage, and promoted apoptosis in resistant cells, ultimately restoring cisplatin sensitivity both in vitro and in vivo.
conclusionsOur study demonstrated that glutamine metabolism plays a vital role in the chemoresistance of GC cells and that RHOJ-derived peptide 1 enhances the chemosensitivity of drug-resistant GC cells through targeting GLUL, depleting glutamine, inducing ROS accumulation, and promoting DNA damage. These mechanisms ultimately restores chemosensitivity in drug-resistant cells and highlight peptide 1 as a promising therapeutic strategy for overcoming chemoresistance in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.